{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:28:14Z","timestamp":1791080894542,"version":"4.1.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current standard of care (SOC) for hepatitis C virus (HCV) infection is the combination of pegylated interferon (PEG-IFN), Ribavirin and protease inhibitor for HCV genotype 1. Nevertheless, this treatment is successful only in 70-80% of the patients. In addition, the treatment is not economical and is of immense physical burden for the subject. It has been established now, that virus-host interactions play a significant role in determining treatment outcomes. Therefore identifying biological markers that may predict the treatment response and hence treatment outcome would be useful. Both IFN and Ribavirin mainly act by modulating the immune system of the patient. Therefore, the treatment response is influenced by genetic variations of the human as well as the HCV genome. The goal of this review article is to summarize the impact of recent scientific advances in this area regarding the understanding of human and HCV genetic variations and their effect on treatment outcomes. Google scholar and PubMed have been used for literature research. Among the host factors, the most prominent associations are polymorphisms within the region of the interleukin 28B (IL28B) gene, but variations in other cytokine genes have also been linked with the treatment outcome. Among the viral factors, HCV genotypes are noteworthy. Moreover, for sustained virological responses (SVR), variations in core, p7, non-structural 2 (NS2), NS3 and NS5A genes are also important. However, all considered single nucleotide polymorphisms (SNPs) of IL28B and viral genotypes are the most important predictors for interferon based therapy of HCV infection.<\/jats:p>","DOI":"10.1186\/1743-422x-10-299","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T09:34:48Z","timestamp":1380620088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of viral and host factors in interferon based therapy of hepatitis C virus infection"],"prefix":"10.1186","volume":"10","author":[{"given":"Muhammad","family":"Imran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muqddas","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Madeha","family":"Khaliq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikandar","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"2285_CR1","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMe048237","volume":"351","author":"JR Wands","year":"2004","unstructured":"Wands JR: Prevention of hepatocellular carcinoma. N Engl J Med 2004, 351: 1567-1570. 10.1056\/NEJMe048237","journal-title":"N Engl J Med"},{"key":"2285_CR2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.20452\/pamw.542","volume":"118","author":"J Czepiel","year":"2008","unstructured":"Czepiel J, Biesiada G, Mach T: Viral hepatitis C. Pol Arch Med Wewn 2008, 118: 734-740.","journal-title":"Pol Arch Med Wewn"},{"key":"2285_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","volume":"3","author":"SL Chen","year":"2006","unstructured":"Chen SL, Morgan TR: The Natural History of Hepatitis C Virus (HCV) infection. Int J Med Sci 2006, 3: 47-52.","journal-title":"Int J Med Sci"},{"key":"2285_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0166-3542(03)00028-7","volume":"58","author":"R De Francesco","year":"2003","unstructured":"De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G: Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003, 58: 1-16. 10.1016\/S0166-3542(03)00028-7","journal-title":"Antiviral Res"},{"key":"2285_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S: Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007, 46: 631-639. 10.1002\/hep.21781","journal-title":"Hepatology"},{"key":"2285_CR6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs A, Lindenmann J: Virus interference. I. the interferon. Proc R SocLond B BiolSci 1957, 147: 258-267. 10.1098\/rspb.1957.0048","journal-title":"Proc R SocLond B BiolSci"},{"key":"2285_CR7","first-page":"20047","volume":"282","author":"S Pestka","year":"2007","unstructured":"Pestka S: The interferons. 50 years after their discovery, there is much more to learn. J BiolChem 2007, 282: 20047-20051.","journal-title":"J BiolChem"},{"key":"2285_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202: 8-32. 10.1111\/j.0105-2896.2004.00204.x","journal-title":"Immunol Rev"},{"key":"2285_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","volume":"77","author":"D Novick","year":"1994","unstructured":"Novick D, Cohen B, Rubinstein M: The human interferon alpha\/beta receptor: characterization and molecular cloning. Cell 1994, 77: 391-400. 10.1016\/0092-8674(94)90154-6","journal-title":"Cell"},{"key":"2285_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(94)90354-9","volume":"76","author":"J Soh","year":"1994","unstructured":"Soh J, Donnelly RJ, Kotenko S, et al.: Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 1994, 76: 793-802. 10.1016\/0092-8674(94)90354-9","journal-title":"Cell"},{"key":"2285_CR11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko SV, Gallagher G, Baurin VV, et al.: IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4: 69-77.","journal-title":"Nat Immunol"},{"key":"2285_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0092-8674(90)90738-Z","volume":"60","author":"G Uze","year":"1990","unstructured":"Uze G, Lutfalla G, Gresser I: Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell 1990, 60: 225-234. 10.1016\/0092-8674(90)90738-Z","journal-title":"Cell"},{"key":"2285_CR13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1189\/jlb.69.6.912","volume":"69","author":"MJ de Veer","year":"2001","unstructured":"de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR: Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001, 69: 912-920.","journal-title":"J Leukoc Biol"},{"key":"2285_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","volume":"67","author":"GR Stark","year":"1998","unstructured":"Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD: How cells respond to interferons. Annu Rev Biochem 1998, 67: 227-264. 10.1146\/annurev.biochem.67.1.227","journal-title":"Annu Rev Biochem"},{"key":"2285_CR15","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.277.5332.1630","volume":"277","author":"JE Darnell","year":"1997","unstructured":"Darnell JE: STATs and gene regulation. Science 1997, 277: 1630-1635. 10.1126\/science.277.5332.1630","journal-title":"Science"},{"key":"2285_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/hep.21312","volume":"44","author":"SE Doyle","year":"2006","unstructured":"Doyle SE, Schreckhise H, Khuu-Duong K, et al.: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44: 896-906. 10.1002\/hep.21312","journal-title":"Hepatology"},{"key":"2285_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.23985","volume":"53","author":"E Thomas","year":"2011","unstructured":"Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, et al.: Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53: 32-41. 10.1002\/hep.23985","journal-title":"Hepatology"},{"key":"2285_CR18","doi-asserted-by":"publisher","first-page":"e27866","DOI":"10.1371\/journal.pone.0027866","volume":"6","author":"NJ Stevenson","year":"2011","unstructured":"Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, O\u2019Farrelly C: Ribavirin enhances IFN-a signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 2011, 6: e27866. 10.1371\/journal.pone.0027866","journal-title":"PLoS One"},{"key":"2285_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152606776056706","volume":"6","author":"C Lin","year":"2006","unstructured":"Lin C, Kwong AD, Perni RB: Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006, 6: 3-16.","journal-title":"Infect Disord Drug Targets"},{"key":"2285_CR20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1073\/pnas.88.6.2451","volume":"88","author":"QL Choo","year":"1991","unstructured":"Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, et al.: Genetic organization and diversity of the hepatitis C virus. Proc Nat AcadSci USA 1991, 88: 2451-2455. 10.1073\/pnas.88.6.2451","journal-title":"Proc Nat AcadSci USA"},{"key":"2285_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/0042-6822(92)90739-C","volume":"188","author":"PJ Chen","year":"1992","unstructured":"Chen PJ, Lin MH, Tai KF, Liu PC, Lin CJ, Chen DS: The Taiwanese hepatitis C virus genome: sequence determination and mapping the 59 termini of viral genomic and antigenomic RNA. Virology 1992, 188: 102-113. 10.1016\/0042-6822(92)90739-C","journal-title":"Virology"},{"key":"2285_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0006-291X(05)81414-7","volume":"181","author":"N Kato","year":"1991","unstructured":"Kato N, Ootsuyama Y, Ohkoshi S, Nakazawa T, Mori S, Hijikata M, Shimotohno K: Distribution of plural HCV types in Japan. Biochem Biophys Res Commun 1991, 181: 279-285. 10.1016\/S0006-291X(05)81414-7","journal-title":"Biochem Biophys Res Commun"},{"key":"2285_CR23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1086\/591252","volume":"198","author":"J Fung","year":"2008","unstructured":"Fung J, Lai CL, Hung I, et al.: Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008, 198: 808-812. 10.1086\/591252","journal-title":"J Infect Dis"},{"key":"2285_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","volume":"17","author":"NH Nguyen","year":"2010","unstructured":"Nguyen NH, Vutien P, Garcia RT, et al.: Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2 \u20443 vs 6. J Viral Hepat 2010, 17: 691-697. 10.1111\/j.1365-2893.2009.01226.x","journal-title":"J Viral Hepat"},{"key":"2285_CR25","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1542-3565(05)00711-1","volume":"3","author":"MH Nguyen","year":"2005","unstructured":"Nguyen MH, Keeffe EB: Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3: S97-S101.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2285_CR26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/ng.453","volume":"41","author":"TR O\u2019Brien","year":"2009","unstructured":"O\u2019Brien TR: Interferon-Alfa, interferon-lambda and hepatitis C. Nat Genet 2009, 41: 1048-1050. 10.1038\/ng.453","journal-title":"Nat Genet"},{"key":"2285_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000087270","volume":"49","author":"MF Yuen","year":"2006","unstructured":"Yuen MF, Lai CL: Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006, 49: 96-98. 10.1159\/000087270","journal-title":"Intervirology"},{"key":"2285_CR28","doi-asserted-by":"publisher","first-page":"16990","DOI":"10.1073\/pnas.0407402101","volume":"101","author":"H Ji","year":"2004","unstructured":"Ji H, Fraser CS, Yu Y, Leary J, Doudna JA: Coordinated assembly of human translation initiation complexes by the hepatitis C virus internal ribosome entry site RNA. Proc Natl Acad Sci USA 2004, 101: 16990-16995. 10.1073\/pnas.0407402101","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3748\/wjg.15.1480","volume":"15","author":"MK El Awady","year":"2009","unstructured":"El Awady MK, Azzazy HM, Fahmy AM, et al.: Positional effect of mutations in 5\u2032UTR of hepatitis C virus 4a on patients\u2019 response to therapy. World J Gastroenterol 2009, 15: 1480-1486. 10.3748\/wjg.15.1480","journal-title":"World J Gastroenterol"},{"key":"2285_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.meegid.2010.11.011","volume":"11","author":"X Xiang","year":"2011","unstructured":"Xiang X, Lu J, Dong Z, Zhou H, Tao W, Guo Q, Zhou X, Bao S, Xie Q, Zhong J: Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment. Infect Genet Evol 2011, 11: 382-390. 10.1016\/j.meegid.2010.11.011","journal-title":"Infect Genet Evol"},{"key":"2285_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00705-012-1283-1","volume":"157","author":"Y Zeng","year":"2012","unstructured":"Zeng Y, Li W, Li J, Wang J, Zhou B, Zhang J, Liu S, Wu Y, Hou J, Zhou Y: Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon\/ribavirin therapy in Chinese patients with chronic hepatitis C. Arch Virol 2012, 157: 1113-1121. 10.1007\/s00705-012-1283-1","journal-title":"Arch Virol"},{"key":"2285_CR32","doi-asserted-by":"publisher","first-page":"e24514","DOI":"10.1371\/journal.pone.0024514","volume":"6","author":"M Kadokura","year":"2011","unstructured":"Kadokura M, Maekawa S, Sueki R, et al.: Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One 2011, 6: e24514. 10.1371\/journal.pone.0024514","journal-title":"PLoS One"},{"key":"2285_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jmv.22005","volume":"83","author":"M Kurosaki","year":"2011","unstructured":"Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N: Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011, 83: 445-452. 10.1002\/jmv.22005","journal-title":"J Med Virol"},{"key":"2285_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2334-11-124","volume":"11","author":"E Alestig","year":"2011","unstructured":"Alestig E, Arnholm B, Eilard A, et al.: Core mutations, IL28B polymorphisms and response to peginterferon\/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011, 11: 124. 10.1186\/1471-2334-11-124","journal-title":"BMC Infect Dis"},{"key":"2285_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hep.23690","volume":"52","author":"N Akuta","year":"2010","unstructured":"Akuta N, Suzuki F, Hirakawa M, et al.: Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010, 52: 421-429. 10.1002\/hep.23690","journal-title":"Hepatology"},{"key":"2285_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/gut.2005.069757","volume":"55","author":"T Asselah","year":"2006","unstructured":"Asselah T, Rubbia-Brandt L, Marcellin P, Negro F: Steatosis in chronic hepatitis C: why does it really matter? Gut 2006, 55: 123-130. 10.1136\/gut.2005.069757","journal-title":"Gut"},{"key":"2285_CR37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1478-3231.2008.01945.x","volume":"29","author":"A Alberti","year":"2009","unstructured":"Alberti A: What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009, 29: 15-18.","journal-title":"Liver Int"},{"key":"2285_CR38","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1086\/651606","volume":"201","author":"TL Mosbruger","year":"2010","unstructured":"Mosbruger TL, Duggal P, Goedert JJ, et al.: Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010, 201: 1371-1380. 10.1086\/651606","journal-title":"J Infect Dis"},{"key":"2285_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/14622416.7.5.697","volume":"7","author":"Y Hwang","year":"2006","unstructured":"Hwang Y, Chen EY, Guetal ZJ: Geneticpredisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics 2006, 7: 697-709. 10.2217\/14622416.7.5.697","journal-title":"Pharmacogenomics"},{"key":"2285_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard P, Kindsvogel W, Xu W, Henderson K, et al.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4: 63-68. 10.1038\/ni873","journal-title":"Nat Immunol"},{"key":"2285_CR41","first-page":"20869","volume":"284","author":"HH Gad","year":"2009","unstructured":"Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R: Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J BiolChem 2009, 284: 20869-20875.","journal-title":"J BiolChem"},{"key":"2285_CR42","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","volume":"4","author":"C Sommereyns","year":"2008","unstructured":"Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008, 4: e1000017. 10.1371\/journal.ppat.1000017","journal-title":"PLoS Pathog"},{"key":"2285_CR43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.4049\/jimmunol.182.3.1296","volume":"182","author":"J Wang","year":"2009","unstructured":"Wang J, Oberley-Deegan R, Wang S, Nikrad M, Funk CJ, Hartshorn KL, Mason RJ: Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda1) in response to influenza A infection. J Immunol 2009, 182: 1296-1304.","journal-title":"J Immunol"},{"key":"2285_CR44","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.4049\/jimmunol.180.4.2474","volume":"180","author":"N Ank","year":"2008","unstructured":"Ank N, Iversen MB, Bartholdy C, Staeheli P, et al.: An important role for type III interferon (IFN-lambda\/IL-28) in TLR-induced antiviral activity. J Immunol 2008, 180: 2474-2485.","journal-title":"J Immunol"},{"key":"2285_CR45","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1128\/JVI.02591-09","volume":"84","author":"MB Iversen","year":"2010","unstructured":"Iversen MB, Ank N, Melchjorsen J, Paludan SR: Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J Virol 2010, 84: 4579-4586. 10.1128\/JVI.02591-09","journal-title":"J Virol"},{"key":"2285_CR46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/eji.200324610","volume":"34","author":"EM Coccia","year":"2004","unstructured":"Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uz\u00e9 G: Viral infection and toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004, 34: 796-805. 10.1002\/eji.200324610","journal-title":"Eur J Immunol"},{"key":"2285_CR47","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"13","author":"T Marcello","year":"2006","unstructured":"Marcello T, Grakoui A, Barba-Spaeth G, et al.: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 13: 1887-1898.","journal-title":"Gastroenterology"},{"key":"2285_CR48","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1128\/JVI.01773-08","volume":"83","author":"W Hou","year":"2009","unstructured":"Hou W, Wang X, Ye L, Zhou L, Yang ZQ, Riedel E, Ho WZ: Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009, 83: 3834-3842. 10.1128\/JVI.01773-08","journal-title":"J Virol"},{"key":"2285_CR49","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1128\/JVI.79.6.3851-3854.2005","volume":"79","author":"MD Robek","year":"2005","unstructured":"Robek MD, Boyd BS, Chisari FV: Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79: 3851-3854. 10.1128\/JVI.79.6.3851-3854.2005","journal-title":"J Virol"},{"key":"2285_CR50","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1189\/jlb.0509347","volume":"86","author":"NJ Megjugorac","year":"2009","unstructured":"Megjugorac NJ, Gallagher GE, Gallagher G: Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leuko Biol 2009, 86: 1359-1363. 10.1189\/jlb.0509347","journal-title":"J Leuko Biol"},{"key":"2285_CR51","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1182\/blood-2005-10-4129","volume":"107","author":"FJ Mennechet","year":"2006","unstructured":"Mennechet FJ, Uz\u00e9 G: Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107: 4417-4423. 10.1182\/blood-2005-10-4129","journal-title":"Blood"},{"key":"2285_CR52","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1189\/jlb.0807525","volume":"83","author":"K Wolk","year":"2008","unstructured":"Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, et al.: Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukocyte Biol 2008, 83: 1181-1193. 10.1189\/jlb.0807525","journal-title":"J Leukocyte Biol"},{"key":"2285_CR53","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al.: Genome wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41: 1105-1109. 10.1038\/ng.449","journal-title":"Nat Genet"},{"key":"2285_CR54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, Simon JS, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461: 399-401. 10.1038\/nature08309","journal-title":"Nature"},{"key":"2285_CR55","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2011.03.006","volume":"55","author":"CM Lange","year":"2011","unstructured":"Lange CM, Zeuzem S: IL28B single nucleotide polymorphisms in the treatment of hepatitis C. Hepatol 2011, 55: 692-701. 10.1016\/j.jhep.2011.03.006","journal-title":"Hepatol"},{"key":"2285_CR56","volume-title":"Pegylated interferon lambda shows superior viral response with improved safety and tolerability versus peg ifn\u03b1 2a in hcv patients (G1\/2\/3\/4) emerge phase IIB through week 12. EASL","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, EMERGE study Group: Pegylated interferon lambda shows superior viral response with improved safety and tolerability versus peg ifn\u03b1 2a in hcv patients (G1\/2\/3\/4) emerge phase IIB through week 12. EASL. Berlin Germany: The International Liver Congress; 2011."},{"key":"2285_CR57","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","volume":"81","author":"S Goodbourn","year":"2000","unstructured":"Goodbourn S, Didcock L, Randall RE: Interferons: cell signaling immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000, 81: 2341-2364.","journal-title":"J Gen Virol"},{"key":"2285_CR58","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1053\/jhep.2002.31770","volume":"35","author":"M Frese","year":"2002","unstructured":"Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, Haller O, Bartenschlager R: Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35: 694-703. 10.1053\/jhep.2002.31770","journal-title":"Hepatology"},{"key":"2285_CR59","first-page":"1412","volume":"27","author":"C Hayden","year":"1997","unstructured":"Hayden C, Pereira E, Rye P, Palmer L, Gibson N, Palenque M, Hagel I, Lynch N, Goldblatt J, Lesouef P: Mutation screening of interferon-gamma (IFNgamma) as a candidate gene for asthma. Clin Exp Allergy 1997, 27: 1412-1416.","journal-title":"Clin Exp Allergy"},{"key":"2285_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s002510050008","volume":"51","author":"JH Bream","year":"2000","unstructured":"Bream JH, Carrington M, O\u2019Toole S, et al.: Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 2000, 51: 50-58. 10.1007\/s002510050008","journal-title":"Immunogenetics"},{"key":"2285_CR61","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1073\/pnas.0609954104","volume":"104","author":"Y Huang","year":"2007","unstructured":"Huang Y, Yang H, Borg BB, et al.: A functional SNP of interferon-\u03b3 gene is important for interferon\u2013induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007, 104: 985-990. 10.1073\/pnas.0609954104","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/1566524013363645","volume":"1","author":"V Apostolopoulos","year":"2001","unstructured":"Apostolopoulos V, McKenzie IF: Role of the mannose receptor in the immune response. Curr Mol Med 2001, 1: 469-474. 10.2174\/1566524013363645","journal-title":"Curr Mol Med"},{"key":"2285_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1365-2249.2008.03614.x","volume":"152","author":"ML AlvesPedroso","year":"2008","unstructured":"AlvesPedroso ML, Boldt AB, Pereira-Ferrari L: Mannan-binding lectin MBL2 gene polymorphism in chronic hepatitis C: association with the severity of liver fibrosis and response to interferon therapy. Clin Exp Immunol 2008, 152: 258-264. 10.1111\/j.1365-2249.2008.03614.x","journal-title":"Clin Exp Immunol"},{"key":"2285_CR64","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1006\/bbrc.2000.3343","volume":"275","author":"S J\u00fcliger","year":"2000","unstructured":"J\u00fcliger S, Luckner D, Mordm\u00fcller B, May J, Weierich A, Lell B, Luty A, Kremsner PG, Kun JF: Promoter variants of the human mannose-binding lectin gene show different binding. Biochem Biophys Res Commun 2000, 275: 617-622. 10.1006\/bbrc.2000.3343","journal-title":"Biochem Biophys Res Commun"},{"key":"2285_CR65","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.4049\/jimmunol.155.6.3013","volume":"155","author":"HO Madsen","year":"1995","unstructured":"Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, Svejgaard A: Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995, 155: 3013-3020.","journal-title":"J Immunol"},{"key":"2285_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0022-1759(00)00198-8","volume":"241","author":"R Steffensen","year":"2000","unstructured":"Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC: Detection of structural gene mutations and promoter polymorphisms in the mannan-bindinglectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods 2000, 241: 33-42. 10.1016\/S0022-1759(00)00198-8","journal-title":"J Immunol Methods"},{"key":"2285_CR67","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/eji.1830181206","volume":"18","author":"P Dariavach","year":"1988","unstructured":"Dariavach P, Mattei MG, Golstein P, Lefranc MP: Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988, 18: 1901-1905. 10.1002\/eji.1830181206","journal-title":"Eur J Immunol"},{"key":"2285_CR68","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.4049\/jimmunol.151.7.3489","volume":"151","author":"T Lindsten","year":"1993","unstructured":"Lindsten T, Lee KP, Harris ES, et al.: Characterization of CTLA-4 structure and expression on human T cells. J Immunol 1993, 151: 3489-3499.","journal-title":"J Immunol"},{"key":"2285_CR69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/sj.gene.6363655","volume":"1","author":"O Kristiansen","year":"2000","unstructured":"Kristiansen O, Larsen Z, Pociot F: CTLA-4 in autoimmune diseases: a general susceptibility gene to autoimmunity? Genes Immun 2000, 1: 170-184. 10.1038\/sj.gene.6363655","journal-title":"Genes Immun"},{"key":"2285_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1006\/bbrc.1996.1256","volume":"225","author":"K Deichmann","year":"1996","unstructured":"Deichmann K, Heinzmann A, Bruggenolte E, Forster J, Kuehr J: An MseI RFLP in the human CTLA4 promotor. Biochem Biophys Res Commun 1996, 225: 817-818. 10.1006\/bbrc.1996.1256","journal-title":"Biochem Biophys Res Commun"},{"key":"2285_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1046\/j.1365-3083.1999.00565.x","volume":"50","author":"MF Liu","year":"1999","unstructured":"Liu MF, Yang CY, Li JS, Lai KA, Chao SC, Lei HY: Increased expression of down-regulatory CTLA-4 molecule on T lymphocytes from rheumatoid synovial compartment. Scand J Immunol 1999, 50: 68-72. 10.1046\/j.1365-3083.1999.00565.x","journal-title":"Scand J Immunol"},{"key":"2285_CR72","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.gene.6363869","volume":"3","author":"XB Wang","year":"2002","unstructured":"Wang XB, Zhao X, Giscombe R, Lefvert AK: A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun 2002, 3: 233-234. 10.1038\/sj.gene.6363869","journal-title":"Genes Immun"},{"key":"2285_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00251-002-0429-9","volume":"54","author":"M Maurer","year":"2002","unstructured":"Maurer M, Loserth S, Kolb-Maurer A, et al.: A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 2002, 54: 1-8. 10.1007\/s00251-002-0429-9","journal-title":"Immunogenetics"},{"key":"2285_CR74","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/sj.gene.6363752","volume":"2","author":"A Ligers","year":"2001","unstructured":"Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J: CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001, 2: 145-152. 10.1038\/sj.gene.6363752","journal-title":"Genes Immun"},{"key":"2285_CR75","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1074-7613(00)80323-4","volume":"5","author":"DJ Lenschow","year":"1996","unstructured":"Lenschow DJ, Herold KC, Rhee L, et al.: CD28\/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996, 5: 285-293. 10.1016\/S1074-7613(00)80323-4","journal-title":"Immunity"},{"key":"2285_CR76","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0092-8674(95)90349-6","volume":"80","author":"VK Kuchroo","year":"1995","unstructured":"Kuchroo VK, Das MP, Brown JA, et al.: B7-1 and B7-2 costimulatory molecules activate differentially the Th1\/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995, 80: 707-718. 10.1016\/0092-8674(95)90349-6","journal-title":"Cell"},{"key":"2285_CR77","doi-asserted-by":"publisher","first-page":"12711","DOI":"10.1073\/pnas.220423597","volume":"97","author":"MS Kuhns","year":"2000","unstructured":"Kuhns MS, Epshteyn V, Sobel RA, Allison JP: Cytotoxic T lymphocyte antigen\u20134 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4 T cells. Proc Natl Acad Sci USA 2000, 97: 12711-12716. 10.1073\/pnas.220423597","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR78","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1086\/374561","volume":"187","author":"LJ Yee","year":"2003","unstructured":"Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA: Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003, 187: 1264-1271. 10.1086\/374561","journal-title":"J Infect Dis"},{"key":"2285_CR79","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cytogfr.2010.09.002","volume":"21","author":"R Sabat","year":"2010","unstructured":"Sabat R, Gr\u00fctz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J: Biology of interleukin-10. Cytokine and Growth Factor Rev 2010, 21: 331-344. 10.1016\/j.cytogfr.2010.09.002","journal-title":"Cytokine and Growth Factor Rev"},{"key":"2285_CR80","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/path.2272","volume":"214","author":"CM Filippi","year":"2008","unstructured":"Filippi CM, von Herrath MG: IL-10 and the resolution of infections. J Pathol 2008, 214: 224-230. 10.1002\/path.2272","journal-title":"J Pathol"},{"issue":"21","key":"2285_CR81","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cytogfr.2010.11.001","volume":"2010","author":"R Sabat","year":"2010","unstructured":"Sabat R: IL-10 family of cytokines. Cytokine and Growth Factor Rev 2010,2010(21):315-324.","journal-title":"Cytokine and Growth Factor Rev"},{"key":"2285_CR82","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1046\/j.1365-2567.2002.01418.x","volume":"106","author":"AS Morel","year":"2002","unstructured":"Morel AS, Coulton G, Londei M: Regulation of major histocompatibility complex class II synthesis by interleukin-10. Immunology 2002, 106: 229-236. 10.1046\/j.1365-2567.2002.01418.x","journal-title":"Immunology"},{"key":"2285_CR83","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2249.1998.00713.x","volume":"114","author":"PA Knolle","year":"1998","unstructured":"Knolle PA, Uhrig A, Hegenbarth S, Loser E, Schmitt E, Gerken G, Lohse AW: IL-10 down-regulates T-cell activation by antigen-presenting liver sinusoidal endothelial cells through decreased antigen uptake via the mannose receptor and lowered surface expression of accessory molecules. Clin Exp Immunol 1998, 114: 427-433. 10.1046\/j.1365-2249.1998.00713.x","journal-title":"Clin Exp Immunol"},{"key":"2285_CR84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.gene.6363656","volume":"1","author":"J Eskdale","year":"1999","unstructured":"Eskdale J, Keijsers V, Huizinga T, Gallagher G: Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999, 1: 151-155. 10.1038\/sj.gene.6363656","journal-title":"Genes Immun"},{"key":"2285_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2370.1997.tb00001.x","volume":"24","author":"D Turner","year":"1997","unstructured":"Turner D, Williams D, Sankaran D, Lazarus M, Sinnott P, Hutchison I: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenetics 1997, 24: 1-8. 10.1111\/j.1365-2370.1997.tb00001.x","journal-title":"Eur J Immunogenetics"},{"key":"2285_CR86","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/hep.1840380412","volume":"38","author":"DR Nelson","year":"2003","unstructured":"Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C, Davis GL: Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatol 2003, 38: 859-868.","journal-title":"Hepatol"},{"key":"2285_CR87","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/jhep.2001.22347","volume":"33","author":"LJ Yee","year":"2001","unstructured":"Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA: Interleukin 10polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatol 2001, 33: 708-712. 10.1053\/jhep.2001.22347","journal-title":"Hepatol"},{"key":"2285_CR88","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1089\/152581601317210863","volume":"10","author":"D Zecchina","year":"2001","unstructured":"Zecchina D, Novick M, Rubinstein V, Barak C, Dinarello H, Nagler A: Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants. J Hematother Stem Cell Res 2001, 10: 769-776. 10.1089\/152581601317210863","journal-title":"J Hematother Stem Cell Res"},{"key":"2285_CR89","first-page":"332","volume":"129","author":"D Kaser","year":"2002","unstructured":"Kaser D, Novick M, Rubeinstein B, Siegmund B, Enrich RO, Koch W, et al.: Interferon-a induces interleukin-18 binding protein in chronic hepatitis C patients. Clin ExpImmunol 2002, 129: 332-338.","journal-title":"Clin ExpImmunol"},{"key":"2285_CR90","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ijc.21367","volume":"118","author":"M Asakawa","year":"2006","unstructured":"Asakawa M, Kono H, Amemiya H, Matsuda M, Suzuki T, Maki A, et al.: Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 2006, 118: 564-570. 10.1002\/ijc.21367","journal-title":"Int J Cancer"},{"key":"2285_CR91","first-page":"415","volume":"35","author":"J Vecchiet","year":"2005","unstructured":"Vecchiet J, Falasca K, Cacciatore P, et al.: Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci 2005, 35: 415-422.","journal-title":"Ann Clin Lab Sci"},{"key":"2285_CR92","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/01.MIB.0000187574.41290.b1","volume":"11","author":"J Glas","year":"2005","unstructured":"Glas J, Torok HP, Tonenchi L, Kapser J, Schiemann U, Muller-Myhsok B, et al.: Association of polymorphisms in the interleu-kin-18 gene in patients with Crohn\u2019s disease depending on the CARD15\/NOD2 genotype. Inflamm Bowel Dis 2005, 11: 1031-1037. 10.1097\/01.MIB.0000187574.41290.b1","journal-title":"Inflamm Bowel Dis"},{"key":"2285_CR93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.104.519702","volume":"112","author":"L Tiret","year":"2005","unstructured":"Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, et al.: Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005, 112: 643-650. 10.1161\/CIRCULATIONAHA.104.519702","journal-title":"Circulation"},{"key":"2285_CR94","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1743-422X-2-88","volume":"2","author":"PA Zhang","year":"2005","unstructured":"Zhang PA, Wu JM, Li Y, Yang XS: A general method for nested RT-PCR amplification and sequencing the complete HCV genotype 1 open reading frame. Virol J 2005, 2: 88. 10.1186\/1743-422X-2-88","journal-title":"Virol J"},{"key":"2285_CR95","doi-asserted-by":"publisher","first-page":"10702","DOI":"10.1128\/JVI.76.21.10702-10707.2002","volume":"76","author":"K Kimura","year":"2002","unstructured":"Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV: Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002, 76: 10702-10707. 10.1128\/JVI.76.21.10702-10707.2002","journal-title":"J Virol"},{"key":"2285_CR96","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00251-006-0104-7","volume":"58","author":"L Segat","year":"2006","unstructured":"Segat L, Bevilacqua D, Boniotto M, Arraes LC, de Souza PR, de Lima Filho JL, et al.: IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics 2006, 58: 471-473. 10.1007\/s00251-006-0104-7","journal-title":"Immunogenetics"},{"key":"2285_CR97","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12072-009-9127-0","volume":"3","author":"K Manohar","year":"2009","unstructured":"Manohar K, Suneetha PV, Sukriti , Pati NT, Gupta AC, Hissar S, Sakhuja P, Sarin SK: Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients. Hepatol Int 2009, 3: 371-377. 10.1007\/s12072-009-9127-0","journal-title":"Hepatol Int"},{"key":"2285_CR98","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3: 673-682. 10.1016\/1074-7613(95)90057-8","journal-title":"Immunity"},{"key":"2285_CR99","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271: 12687-12690. 10.1074\/jbc.271.22.12687","journal-title":"J Biol Chem"},{"key":"2285_CR100","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/156652409788167078","volume":"9","author":"N Cummins","year":"2009","unstructured":"Cummins N, Badley A: The TRAIL to viral pathogenesis: the good, the bad and the ugly. Curr Mol Med 2009, 9: 495-505. 10.2174\/156652409788167078","journal-title":"Curr Mol Med"},{"key":"2285_CR101","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1097\/QAD.0b013e32833eacfd","volume":"24","author":"SA Rizza","year":"2010","unstructured":"Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD: Polymorphism in tumor necrosis factor-related apoptosis-inducing ligandreceptor1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV\/hepatitis C virus-co infected individuals. AIDS 2010, 24: 2639-2644. 10.1097\/QAD.0b013e32833eacfd","journal-title":"AIDS"},{"key":"2285_CR102","first-page":"714","volume":"26","author":"ZG Su","year":"2005","unstructured":"Su ZG, Wen FQ, Feng YL, Xiao M, Wu XL: Transforming growth factor-beta 1 gene polymorphism associated with chronic obstructive pulmonary disease in Chinese population. Acta Pharmacol Sin 2005, 26: 714-720.","journal-title":"Acta Pharmacol Sin"},{"key":"2285_CR103","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2005.02.047","volume":"9","author":"RL Elliott","year":"2005","unstructured":"Elliott RL, Blobe GC: Role of transforming growth factor beta in human cancer. J clinoncol 2005, 9: 2078-2088.","journal-title":"J clinoncol"},{"key":"2285_CR104","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1097\/QAD.0b013e3282f85daa","volume":"22","author":"J Nattermann","year":"2008","unstructured":"Nattermann J, Vogel M, Nischalke HD, et al.: The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C. AIDS 2008, 22: 1287-1292. 10.1097\/QAD.0b013e3282f85daa","journal-title":"AIDS"},{"key":"2285_CR105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115: 209-218.","journal-title":"J Clin Invest"},{"key":"2285_CR106","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.biochi.2007.04.015","volume":"89","author":"O Haller","year":"2007","unstructured":"Haller O, Staeheli P, Kochs G: Interferon-induced Mx proteins in antiviral host defense. Biochimie 2007, 89: 812-818. 10.1016\/j.biochi.2007.04.015","journal-title":"Biochimie"},{"key":"2285_CR107","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1006\/viro.1996.0321","volume":"220","author":"H Zhao","year":"1996","unstructured":"Zhao H, De BP, Das T, Banerjee AK: Inhibition of human parainfluenza virus-3 replication by interferon and human MxA. Virol 1996, 220: 330-338. 10.1006\/viro.1996.0321","journal-title":"Virol"},{"key":"2285_CR108","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/hep.1840190409","volume":"19","author":"D Jakschies","year":"1994","unstructured":"Jakschies D, Zachoval R, Muller R, et al.: Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C. Hepatol 1994, 19: 857-865.","journal-title":"Hepatol"},{"key":"2285_CR109","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1086\/314859","volume":"180","author":"M Ferna\u2019ndez","year":"1999","unstructured":"Ferna\u2019ndez M, Antonio J, Quiroga JA, et al.: In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999, 180: 262-267. 10.1086\/314859","journal-title":"J Infect Dis"},{"key":"2285_CR110","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000025035","volume":"43","author":"M Hijikata","year":"2000","unstructured":"Hijikata M, Ohta Y, Mishiro S: Identification of a single nucleotide polymorphism in the MxA gene promoter (G\/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirol 2000, 43: 124-127. 10.1159\/000025035","journal-title":"Intervirol"},{"key":"2285_CR111","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2893.2004.00509.x","volume":"11","author":"F Suzuki","year":"2004","unstructured":"Suzuki F, Arase Y, Suzuki Y, et al.: Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004, 11: 271-280. 10.1111\/j.1365-2893.2004.00509.x","journal-title":"J Viral Hepat"},{"key":"2285_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W","volume":"33","author":"MD McKee","year":"1996","unstructured":"McKee MD, Nanci A: Osteopontin at mineralized tissue interfaces in bone, teeth, and osseointegrated implants: ultrastructural distribution and implications for mineralized tissue formation, turnover, and repair. Microsc Res Tech 1996, 33: 141-164. 10.1002\/(SICI)1097-0029(19960201)33:2<141::AID-JEMT5>3.0.CO;2-W","journal-title":"Microsc Res Tech"},{"key":"2285_CR113","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/1055-9965.EPI-06-1008","volume":"16","author":"LR Rodrigues","year":"2007","unstructured":"Rodrigues LR, Teixeira JA, Schmitt FL, Paulsson M, Lindmark-M\u00e4nsson H: The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 2007, 16: 1087-1097. 10.1158\/1055-9965.EPI-06-1008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2285_CR114","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1073\/pnas.052523599","volume":"99","author":"K Yumoto","year":"2002","unstructured":"Yumoto K, Ishijima M, Rittling SR, et al.: Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002, 99: 4556-4561. 10.1073\/pnas.052523599","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR115","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1002\/art.20381","volume":"50","author":"JP Jacobs","year":"2004","unstructured":"Jacobs JP, Pettit AR, Shinohara ML, et al.: Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K\/BxN model of autoantibody-mediated arthritis. Arthritis Rheum 2004, 50: 2685-2694. 10.1002\/art.20381","journal-title":"Arthritis Rheum"},{"key":"2285_CR116","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cytogfr.2008.08.001","volume":"19","author":"KX Wang","year":"2008","unstructured":"Wang KX, Denhardt DT: Osteopontin:role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008, 19: 333-345. 10.1016\/j.cytogfr.2008.08.001","journal-title":"Cytokine Growth Factor Rev"},{"key":"2285_CR117","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s005350070049","volume":"35","author":"Y Wang","year":"2000","unstructured":"Wang Y, Mochida S, Kawashima R, et al.: Increased expression of osteopontin in activated kupffer cells and hepatic macrophages during macrophage migration in propionibacterium acnes-treated rat liver. J Gastroenterol 2000, 35: 696-701. 10.1007\/s005350070049","journal-title":"J Gastroenterol"},{"key":"2285_CR118","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.287.5454.860","volume":"287","author":"S Ashkar","year":"2000","unstructured":"Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al.: Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000, 287: 860-864. 10.1126\/science.287.5454.860","journal-title":"Science"},{"key":"2285_CR119","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.bbrc.2003.12.045","volume":"313","author":"S Mochida","year":"2004","unstructured":"Mochida S, Hashimoto M, Matsui A, Naito M, Inao M, Nagoshi S, et al.: Genetic polymorphysms in promoter region of osteopontin gene as a marker for predicting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004, 313: 1079-1085. 10.1016\/j.bbrc.2003.12.045","journal-title":"Biochem Biophys Res Commun"},{"key":"2285_CR120","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00535-005-1558-3","volume":"40","author":"M Naito","year":"2005","unstructured":"Naito M, Matsui A, Inao M, Nagoshi S, et al.: SNPs in the promoter region of the osteopontingene as a markerpredicting the efficacy of interferon-basedtherapies in patients with chronic hepatitis C. J Gastroenterol 2005, 40: 381-388. 10.1007\/s00535-005-1558-3","journal-title":"J Gastroenterol"},{"key":"2285_CR121","doi-asserted-by":"publisher","first-page":"9213","DOI":"10.1073\/pnas.91.20.9213","volume":"91","author":"M Gaczynska","year":"1994","unstructured":"Gaczynska M, Rock KL, Spies T, Goldberg AL: Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc Natl Acad Sci USA 1994, 91: 9213-9217. 10.1073\/pnas.91.20.9213","journal-title":"Proc Natl Acad Sci USA"},{"key":"2285_CR122","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1002\/eji.1830250930","volume":"25","author":"U Kuckelkorn","year":"1995","unstructured":"Kuckelkorn U, Frentzel S, Kraft R, Kostka S, Groettrup M, Kloetzel PM: Incorporation of major histocompatibility complex-encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-\u03b3. Eur J Immunol 1995, 25: 2605-2611. 10.1002\/eji.1830250930","journal-title":"Eur J Immunol"},{"key":"2285_CR123","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1046\/j.1365-2893.2002.00365.x","volume":"9","author":"Y Sugimoto","year":"2002","unstructured":"Sugimoto Y, Kuzushita N, Takehara T, et al.: A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepat 2002, 9: 377-384. 10.1046\/j.1365-2893.2002.00365.x","journal-title":"J Viral Hepat"},{"key":"2285_CR124","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.bbrc.2005.02.101","volume":"329","author":"E Hamano","year":"2005","unstructured":"Hamano E, Hijikata M, Itoyama S, et al.: Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun 2005, 329: 1234-1242. 10.1016\/j.bbrc.2005.02.101","journal-title":"Biochem Biophys Res Commun"},{"key":"2285_CR125","first-page":"6795","volume":"63","author":"Y Xiang","year":"2003","unstructured":"Xiang Y, Wang Z, Murakami J, et al.: Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2\u2032-5\u2032-oligoadenylates. Cancer Res 2003, 63: 6795-6801.","journal-title":"Cancer Res"},{"key":"2285_CR126","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1440-1746.2010.06605.x","volume":"26","author":"MK El Awady","year":"2011","unstructured":"El Awady MK, Anany MA, Esmat G, et al.: Single nucleotide polymorphism at exon7splice acceptor site of OAS1genedeterminesresponse of hepatitis C viruspatients to interferontherapy. J Gastroenterol Hepatol 2011, 26: 843-850. 10.1111\/j.1440-1746.2010.06605.x","journal-title":"J Gastroenterol Hepatol"},{"key":"2285_CR127","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2893.2009.01122.x","volume":"16","author":"KR Reddy","year":"2009","unstructured":"Reddy KR, Messinger D, Popescu M, Hadziyannis SJ: Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009, 16: 724-731. 10.1111\/j.1365-2893.2009.01122.x","journal-title":"J Viral Hepat"},{"key":"2285_CR128","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1286-4579(01)01443-5","volume":"3","author":"L Ginaldi","year":"2001","unstructured":"Ginaldi L, Loreto MF, Corsi MP, Modesti M, De Martinis M: Immunosenescence and infectious diseases. Microbes Infect 2001, 3: 851-857. 10.1016\/S1286-4579(01)01443-5","journal-title":"Microbes Infect"},{"key":"2285_CR129","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/hep.510300319","volume":"30","author":"KR Reddy","year":"1999","unstructured":"Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus interferon study group. Hepatol 1999, 30: 787-793. 10.1002\/hep.510300319","journal-title":"Hepatol"},{"key":"2285_CR130","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","volume":"131","author":"HS Conjeevaram","year":"2006","unstructured":"Conjeevaram HS, Fried MW, Jeffers LJ, et al.: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterol 2006, 131: 470-477. 10.1053\/j.gastro.2006.06.008","journal-title":"Gastroenterol"},{"key":"2285_CR131","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1053\/gast.2000.19289","volume":"119","author":"JG McHutchison","year":"2000","unstructured":"McHutchison JG, Poynard T, Pianko S, et al.: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The international hepatitis interventional therapy group. Gastroenterol 2000, 119: 1317-1323. 10.1053\/gast.2000.19289","journal-title":"Gastroenterol"},{"key":"2285_CR132","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ajg.2010.370","volume":"106","author":"PJ Clark","year":"2011","unstructured":"Clark PJ, Thompson AJ, McHutchison JG: IL28Bgenomic-Basedtreatmentparadigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011, 106: 38-45. 10.1038\/ajg.2010.370","journal-title":"Am J Gastroenterol"},{"key":"2285_CR133","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","volume":"352","author":"T Poynard","year":"1998","unstructured":"Poynard T, Marcellin P, Lee SS, et al.: Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352: 1426-1432. 10.1016\/S0140-6736(98)07124-4","journal-title":"Lancet"},{"key":"2285_CR134","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358: 958-965. 10.1016\/S0140-6736(01)06102-5","journal-title":"Lancet"},{"key":"2285_CR135","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1111\/j.1572-0241.2002.05995.x","volume":"97","author":"V Ortiz","year":"2002","unstructured":"Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J: Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 2002, 97: 2408-2414. 10.1111\/j.1572-0241.2002.05995.x","journal-title":"Am J Gastroenterol"},{"key":"2285_CR136","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/jhep.2003.50350","volume":"38","author":"BL Bressler","year":"2003","unstructured":"Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatol 2003, 38: 639-644.","journal-title":"Hepatol"},{"key":"2285_CR137","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S0168-8278(03)00463-X","volume":"39","author":"IJ Hickman","year":"2003","unstructured":"Hickman IJ, Powell EE, Prins JB, et al.: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003, 39: 1042-1048. 10.1016\/S0168-8278(03)00463-X","journal-title":"J Hepatol"},{"key":"2285_CR138","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/hep.21239","volume":"43","author":"MR Charlton","year":"2006","unstructured":"Charlton MR, Pockros PJ, Harrison SA: Impact of obesity on treatment of chronic hepatitis C. Hepatol 2006, 43: 1177-1186. 10.1002\/hep.21239","journal-title":"Hepatol"},{"key":"2285_CR139","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/hep.21932","volume":"46","author":"IM Jacobson","year":"2007","unstructured":"Jacobson IM, Brown RS Jr, Freilich B, et al.: Peginterferon alfa-2b and weight-based or flat dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatol 2007, 46: 971-981. 10.1002\/hep.21932","journal-title":"Hepatol"},{"key":"2285_CR140","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/gut.51.1.89","volume":"51","author":"IJ Hickman","year":"2002","unstructured":"Hickman IJ, Clouston AD, MacDonald GA, et al.: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51: 89-94. 10.1136\/gut.51.1.89","journal-title":"Gut"},{"key":"2285_CR141","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349: 825-832. 10.1016\/S0140-6736(96)07642-8","journal-title":"Lancet"},{"key":"2285_CR142","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/MCG.0b013e3180381584","volume":"41","author":"AK Singal","year":"2007","unstructured":"Singal AK, Anand BS: Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007, 41: 761-772. 10.1097\/MCG.0b013e3180381584","journal-title":"J Clin Gastroenterol"},{"key":"2285_CR143","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1572-0241.2005.40429.x","volume":"100","author":"CO Zein","year":"2005","unstructured":"Zein CO, Levy C, Basu A, Zein NN: Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol 2005, 100: 48-55. 10.1111\/j.1572-0241.2005.40429.x","journal-title":"Am J Gastroenterol"},{"key":"2285_CR144","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/01.mcg.0000190774.91875.d2","volume":"40","author":"SA Harrison","year":"2006","unstructured":"Harrison SA: Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006, 40: 68-76. 10.1097\/01.mcg.0000190774.91875.d2","journal-title":"J Clin Gastroenterol"},{"key":"2285_CR145","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/gut.2005.069674","volume":"55","author":"MJ Walsh","year":"2006","unstructured":"Walsh MJ, Jonsson JR, Richardson MM, et al.: Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55: 529-535. 10.1136\/gut.2005.069674","journal-title":"Gut"},{"key":"2285_CR146","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"A Commentary","year":"2001","unstructured":"Commentary A, Interactive F, Page P, Video F: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285: 2486-2497. 10.1001\/jama.285.19.2486","journal-title":"JAMA"},{"key":"2285_CR147","first-page":"707","volume":"44","author":"MA Khattab","year":"2010","unstructured":"Khattab MA, Abdel-fattah ME, Eslam M, Abdelaleem A, Abdelaleem RA, Shatat M, et al.: Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. JClin Gastroenterol 2010, 44: 707-712.","journal-title":"JClin Gastroenterol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-10-299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T15:05:48Z","timestamp":1746025548000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-10-299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-10-299","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]},"assertion":[{"value":"4 March 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"299"}}